Carrat F, et al. - In the French ANRS CO22 Hepather cohort, researchers compared clinical outcomes (including the incidence of death, hepatocellular carcinoma, and decompensated cirrhosis) in patients treated with direct-acting antivirals for chronic hepatitis C virus (HCV) infection vs those untreated. Patients with chronic hepatitis B, with a history of decompensated cirrhosis, hepatocellular carcinoma, or liver transplantation, and those treated with interferon-ribavirin with or without first-generation protease inhibitors were excluded from the study. Participants were followed for a median duration of 33.4 months. Overall, of 10,166 eligible patients, 9,895 (97%) had available follow-up information and were included in this study. A lower risk for mortality and hepatocellular carcinoma was observed in relation to treatment with direct-acting antivirals; considering these agents in all patients with chronic HCV infection was recommended.